Scholars@Duke
David Morris Marks

David Morris Marks

Adjunct Associate Professor in the Department of Psychiatry and Behavioral Sciences
Psychiatry & Behavioral Sciences, Adult Psychiatry & Psychology
d.marks@duke.edu
Box 3333 Med Ctr, DUMC, Durham, NC 27710
932 Morreene Road, Durham, NC 27705

Selected Publications

Marked gender differences in progression of mild cognitive impairment over 8 years.

Journal Article Alzheimers Dement (N Y) · September 1, 2015 INTRODUCTION: This study examined whether, among subjects with mild cognitive impairment (MCI), women progressed at faster rates than men. METHODS: We examine longitudinal rates of change from baseline in 398 MCI subjects (141 Females, 257 Males) in the Al ... Full text Link to item Cite

Durability of Benefit From Repeated Intravenous Lidocaine Infusions in Fibromyalgia Patients: A Case Series and Literature Review.

Journal Article Prim Care Companion CNS Disord · 2015 Fibromyalgia is a painful disorder with no curative treatments, and available medications typically provide partial relief of pain. Reported here is the effective use of serial intravenous lidocaine infusions for the chronic management of 3 patients with f ... Full text Link to item Cite

A double-blind, placebo-controlled, parallel-group pilot study of milnacipran for chronic radicular pain (sciatica) associated with lumbosacral disc disease.

Journal Article Prim Care Companion CNS Disord · 2014 OBJECTIVE: The current study investigates whether milnacipran, an equipotent serotonin-norepinephrine reuptake inhibitor, is effective in reducing chronic radicular pain in patients (N = 11) with lumbosacral disc disease. METHOD: This study is a 10-week ra ... Full text Link to item Cite

Effects of milnacipran on neurocognition, pain, and fatigue in fibromyalgia: a 13-week, randomized, placebo-controlled, crossover trial.

Journal Article Prim Care Companion CNS Disord · 2013 OBJECTIVE: To investigate whether milnacipran is safe and effective in improving cognitive function in patients with fibromyalgia. METHOD: Patients were randomly assigned to receive milnacipran or placebo for 6 weeks, followed by a 1-week washout and then ... Full text Link to item Cite

Open-label milnacipran for patients with persistent knee pain 1 year or longer after total knee arthroplasty: a pilot study.

Journal Article Prim Care Companion CNS Disord · 2013 OBJECTIVE: The current study investigates whether milnacipran is effective in reducing pain and improving function in patients with persistent pain ≥ 1 year after total knee arthroplasty. METHOD: This was a 12-week open-label study of flexibly dosed milnac ... Full text Link to item Cite

Amitifadine hydrochloride: Triple reuptake inhibitor treatment of depression

Journal Article Drugs of the Future · April 1, 2012 Amitifadine (EB-1010, DOV-21947) is a "triple reuptake inhibitor" that inhibits the reuptake of serotonin, norepinephrine and dopamine with relative in vitro potencies of 1:2:8. In addition to this in vitro receptor profile, in vivo microdialysis studies d ... Full text Cite

Amitifadine hydrochloride: Triple reuptake inhibitor treatment of depression

Journal Article Drugs of the Future · January 1, 2012 Amitifadine (EB-1010, DOV-21947) is a "triple reuptake inhibitor" that inhibits the reuptake of serotonin, norepinephrine and dopamine with relative in vitro potencies of 1:2:8. In addition to this in vitro receptor profile, in vivo microdialysis studies d ... Full text Cite

Impact of olanzapine or risperidone treatment on insulin sensitivity in schizophrenia or schizoaffective disorder.

Journal Article Diabetes Obes Metab · August 2011 AIM: To assess changes in insulin sensitivity in non-diabetic adults with schizophrenia or schizoaffective disorder treated with olanzapine or risperidone. METHODS: One hundred and thirty patients were randomly assigned to 12 weeks double-blind treatment w ... Full text Link to item Cite

Serotonin-norepinephrine reuptake inhibitors for pain control: premise and promise.

Journal Article Curr Neuropharmacol · December 2009 The precise mechanisms of pain perception and transmission in the central nervous system have not been fully elucidated. However, extensive data support a role for the monoamine neurotransmitters, serotonin and norepinephrine, in the modulation of pain. Ex ... Full text Link to item Cite

Atypical depression: a comprehensive review.

Journal Article CNS Drugs · December 2009 Despite several decades of research, the characteristics distinguishing atypical depression from other depressive subtypes remain ambiguous. Multiple lines of evidence support the designation of atypical depression as a scientifically and clinically releva ... Full text Link to item Cite

History of depressive and/or anxiety disorders as a predictor of treatment response: a post hoc analysis of a 12-week, randomized, double-blind, placebo-controlled trial of paroxetine controlled release in patients with fibromyalgia.

Journal Article Prog Neuropsychopharmacol Biol Psychiatry · August 31, 2009 BACKGROUND: Despite of a high comorbidity of depressive and/or anxiety disorders with fibromyalgia, information on the clinical implications of this comorbidity is limited but antidepressants are commonly prescribed to treat fibromyalgia in clinical practi ... Full text Link to item Cite

Pharmacological treatment of chronic fatigue syndrome: focusing on the role of antidepressants.

Journal Article Expert Opin Pharmacother · July 2009 Chronic fatigue syndrome (CFS) is characterized by chronic, medically unexplained fatigue associated with effort- and stress-intolerance, widespread pain, and impairment in sleep and concentration. Although this constellation of symptoms is highly prevalen ... Full text Link to item Cite

Does pregabalin have neuropsychotropic effects?: a short perspective.

Journal Article Psychiatry Investig · June 2009 Pregabalin is a newly developed synthetic gamma-aminobutyric acid (GABA) that is approved for the treatment of fibromyalgia and several neuropathy. It has been proven to show analgesic, anxiolytic, anticonvulsant and sleep enhancement effects, which could ... Full text Link to item Cite

The impact of the CONSORT statement on reporting of randomized clinical trials in psychiatry.

Journal Article Contemp Clin Trials · March 2009 To determine whether the CONSORT recommendations influenced the quality of reporting of randomized controlled trials (RCTs) in the field of psychiatry, we evaluated the quality of clinical trial reports before and after the introduction of CONSORT statemen ... Full text Open Access Link to item Cite

Effectiveness of antidepressant treatments in pre-menopausal versus post-menopausal women: a pilot study on differential effects of sex hormones on antidepressant effects.

Journal Article Biomed Pharmacother · March 2009 The incidence or recurrence of major depression is greatly increased in women during the transition to and after menopause and hormonal changes occurring during these periods are thought to play an important role in depressive recurrence. It has been also ... Full text Link to item Cite

Innovations in clinical research design and conduct in psychiatry: shifting to pragmatic approaches.

Journal Article Psychiatry Investig · March 2009 The classically structured clinical trial does not offer enough flexibility to make use of continuously emerging knowledge that is generated as the trial progresses. In this regard, there are consistent issues impeding effective psychiatric research, inclu ... Full text Link to item Cite

Methylphenidate extended release (OROS MPH) for the treatment of antidepressant-related sexual dysfunction in patients with treatment-resistant depression: results from a 4-week, double-blind, placebo-controlled trial.

Journal Article Clin Neuropharmacol · 2009 There are limited data to indicate effective treatment strategies for antidepressant-related sexual dysfunction, in particular for patients with treatment-resistant major depression. We subanalyzed our published data whether augmentation with methylphenida ... Full text Link to item Cite

History of early abuse as a predictor of treatment response in patients with fibromyalgia: a post-hoc analysis of a 12-week, randomized, double-blind, placebo-controlled trial of paroxetine controlled release.

Journal Article World J Biol Psychiatry · 2009 OBJECTIVES: We conducted a post-hoc analysis to determine whether a history of physical or sexual abuse was associated with response to treatment in a double-blind, randomized, placebo-controlled trial of paroxetine controlled release (CR) in fibromyalgia. ... Full text Link to item Cite

Milnacipran: beyond a role of antidepressant.

Journal Article Clin Neuropharmacol · 2009 Milnacipran is a serotonin and norepinephrine reuptake inhibitor (SNRI) with negligible effects on any presynaptic or postsynaptic receptors. Milnacipran has unique pharmacokinetic and pharmacodynamic characteristics that distinguish it from the other mark ... Full text Link to item Cite

Pregabalin augmentation of antidepressants in patients with accident-related posttraumatic stress disorder: an open label pilot study.

Journal Article Int Clin Psychopharmacol · January 2009 This study evaluated the efficacy of pregabalin augmentation of antidepressant treatment in patients with posttraumatic stress disorder (PTSD). Nine patients meeting Diagnostic and Statistical Manual, fourth edition criteria for PTSD who were on stable dos ... Full text Link to item Cite

Desvenlafaxine, a serotonin-norepinephrine uptake inhibitor for major depressive disorder, neuropathic pain and the vasomotor symptoms associated with menopause.

Journal Article Curr Opin Investig Drugs · January 2009 Desvenlafaxine, a serotonin-norepinephrine reuptake inhibitor (SNRI) developed by Wyeth, is a novel salt form of the isolated major active metabolite of the antidepressant venlafaxine. Desvenlafaxine was developed as a slow-release tablet formulation and r ... Link to item Cite

Duloxetine: an emerging evidence for fibromyalgia.

Journal Article Biomed Pharmacother · January 2009 Full text Link to item Cite

Triple reuptake inhibitors: the next generation of antidepressants.

Journal Article Curr Neuropharmacol · December 2008 Depression has been associated with impaired neurotransmission of serotonergic, norepinephrinergic, and dopaminergic pathways, although most pharmacologic treatment strategies for depression enhance only serotonin and norepinephrine neurotransmission. Curr ... Full text Link to item Cite

Paroxetine: safety and tolerability issues.

Journal Article Expert Opin Drug Saf · November 2008 Paroxetine is a selective serotonin re-uptake inhibitor (SSRI) available in immediate release and controlled release (CR) formulations. Paroxetine is the most potent inhibitor of serotonin re-uptake among the now available SSRIs. Paroxetine has been approv ... Full text Link to item Cite

Does neurotropin-3 have a therapeutic implication in major depression?

Journal Article Int J Neurosci · November 2008 Although several classes of antidepressants are used to treat major depression, there is an unmet need in real clinical practice because not all patients treated with an antidepressant fully recover from their functional impairment. Hence, the development ... Full text Link to item Cite

Triple reuptake inhibitors: a premise and promise.

Journal Article Psychiatry Investig · September 2008 On the horizon there is a new class of psychoactive medications which work by inhibiting the neuronal reuptake of serotonin, norepinephrine, and dopamine. There are multiple potential indications for these drugs. Research suggests that they may have a role ... Full text Link to item Cite

Delirium: underrecognized and undertreated.

Journal Article Curr Treat Options Neurol · September 2008 Delirium is a complex neuropsychiatric syndrome presenting primarily with disturbances of cognition, perception and sensorium, alertness, sleep/wake cycle, and psychomotor behavior in the context of a medical etiology. The presentation can be quite variabl ... Full text Link to item Cite

The relationship between fibromyalgia and major depressive disorder: a comprehensive review.

Journal Article Curr Med Res Opin · August 2008 OBJECTIVE: A large body of evidence suggests that the relationship between major depressive disorder (MDD) and fibromyalgia (FM) is complex. Improved understanding of this relationship promises to provide clinicians with better assessment and treatment opt ... Full text Link to item Cite

Delirium: where do we stand?

Journal Article Curr Psychiatry Rep · June 2008 Clinicians are likely to encounter delirium frequently, particularly in inpatient and intensive care settings. However, delirium is underrecognized and undertreated because of its heterogeneous and fluctuating presentation and due to the limitations in res ... Full text Link to item Cite

Paroxetine for patients with undifferentiated somatoform disorder: A prospective, open-label, 8-week pilot study.

Journal Article Curr Ther Res Clin Exp · June 2008 BACKGROUND: Forty-eight percent of somatic symptoms encountered in the primary care setting are medically unexplained. Such symptoms have been associated with negative impact on quality of life and with functional impairment. OBJECTIVE: The aim of this stu ... Full text Link to item Cite

Does minocycline have antidepressant effect?

Journal Article Biomed Pharmacother · June 2008 Only one-third of patients undergoing monotherapy with an antidepressant achieve remission of their depressive symptoms and gain functional recovery. Therefore, further exploration of antidepressant mechanisms of action is important in order to facilitate ... Full text Link to item Cite

An open-label, rater-blinded, flexible-dose, 8-week trial of escitalopram in patients with major depressive disorder with atypical features.

Journal Article Prim Care Companion J Clin Psychiatry · 2008 OBJECTIVES: Although selective serotonin reuptake inhibitors (SSRIs) have become the standard of care for the treatment of major depressive disorder (MDD), limited data exist to support their use in MDD with atypical features. The current study investigate ... Full text Link to item Cite

History of depressive and anxiety disorders and paroxetine response in patients with irritable bowel syndrome: post hoc analysis from a placebo-controlled study.

Journal Article Prim Care Companion J Clin Psychiatry · 2008 OBJECTIVE: Although irritable bowel syndrome (IBS) is highly comorbid with depressive and anxiety disorders, information on the clinical implications of this comorbidity is limited. We investigated whether a history of depressive and/or anxiety disorders w ... Full text Link to item Cite

Quetiapine monotherapy in the treatment of patients with bipolar I or II depression and a rapid-cycling disease course: a randomized, double-blind, placebo-controlled study.

Journal Article Bipolar Disord · June 2007 OBJECTIVES: To investigate the efficacy and tolerability of quetiapine monotherapy in patients with bipolar I or II disorder with a rapid-cycling disease course. METHODS: Adult patients with a DSM-IV diagnosis of bipolar disorder, most recent episode depre ... Full text Link to item Cite

Fluoroscopic imaging guides of the posterior pelvis pertaining to iliosacral screw placement.

Journal Article J Trauma · February 2007 BACKGROUND: This study correlates anatomic landmarks with radiographic densities and radiolucencies of the posterior pelvis, which assists in percutaneous iliosacral screw placement. METHODS: Radio-opaque markers were placed on selected surfaces of cadaver ... Full text Link to item Cite

A survey of medical toxicology training in psychiatry residency programs.

Journal Article Acad Psychiatry · 2003 OBJECTIVE: To determine the extent of medical toxicology training provided in U.S. psychiatry residency programs. Medical toxicology is a newly recognized field of medicine. Many patient consultations are common to psychiatrists and medical toxicologists, ... Full text Link to item Cite